945 
Sanofi-Aventis has received a boost from the French agency which deals with reimbursement after it gave a favourable recommendation for the use of the firm’s obesity and diabetes drug rimonabant (Acomplia).
↓Article continues below this sponsored advert↓
Explore the latest advances in respiratory care at events delivered by renowned experts from CofE
↑Advertisement↑
The Transparency Committee (Commission de la Transparence) has recommended that the government reimburse rimonabant for obese patients who are unable to control their type 2 diabetes with a monotherapy of metformin or a sulfonylurea, and who have an HBA1c level of between 6.5% and 10%. The committee has also suggested that the treatment should be combined with diet and physical activity.
